Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203).Michele Maio, Tibor Csőszi, Sulabha Ranganathan et al.|Journal of Clinical Oncology|2021Cited by 7